News Related to Amycretin

Related coverage linked through entity extraction aliases.

Novo Nordisk Faces Competitive Pressure in Weight Loss Market Despite New Drug Developments

Mar 08, 2026

Novo Nordisk struggles against Eli Lilly in the weight loss market as CagriSema underperforms Zepbound, though new candidate UBT251 shows promise with 19.7% weight loss in 24 weeks. The company expects sales to decline in 2026 despite oral Wegovy's success.

Novo Nordisk's CagriSema Outperforms Ozempic in Phase 3 Diabetes Trial

Feb 17, 2026

Novo Nordisk's investigational dual agonist CagriSema demonstrated superior efficacy to Ozempic in a phase 3 trial for type 2 diabetes patients, while the company faces market share losses to Eli Lilly in the GLP-1 space.